What Henogen does

Henogen is a privately held Belgian biotechnology company founded in 1999 and headquartered in Gosselies, Belgium. The firm operates in biomanufacturing services with a stated scope spanning gene development through clinical-product manufacturing — described in the firmographic input as "from gene to the clinical product." With 11-50 employees, Henogen is positioned as a small specialist operator in the European biomanufacturing services market, likely serving biotechnology and pharmaceutical developers requiring process development or GMP manufacturing support. End-customer composition, named accounts, and contract structures are not documented in the available source.

Henogen's specific product set, technology platforms, modalities served, and facility footprint are not documented in the available source data. The aggregated input attributes detailed capability descriptions — small molecule, large molecule, biologics, advanced therapies (viral vectors, mRNA), clinical trial services, commercial manufacturing — to Patheon pharma services, the Contract Development and Manufacturing Organization (CDMO) business unit of Thermo Fisher Scientific (NYSE: TMO). This Patheon-specific content does not reconcile with Henogen's firmographic identity as a private 11-50-employee Belgian biotech and is treated as a data-aggregation artifact rather than as evidence of Henogen's product or technology footprint. Henogen's actual technical capabilities, certifications, and platform architecture cannot be specified from the available data.

Henogen's revenue model, pricing approach, and go-to-market mechanics are not documented in the input. No customer logos, named segments, pricing tiers, or revenue splits are provided for the entity. For a 25-employee biomanufacturing firm in Belgium, structurally plausible revenue models include project-based development services, contract manufacturing, or technology licensing — but each is an unverified inference rather than a documented fact. The firmographic data indicates a for-profit, privately held company with no public financial disclosures available.

Name

Henogen

Legal name

Thermo Fisher Scientific Inc.

Website

https://henogen.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

Henogen is a privately held Belgian biotechnology company headquartered in Gosselies, founded in 1999. The firm operates in biomanufacturing services spanning gene development through clinical-product manufacturing for biotech and pharmaceutical clients.

Ownership category

akta.pro rank

Headquarters

HQ city

Gosselies

HQ country

Belgium

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. CDMO Contract Manufacturing Services: Revenue generated from providing contract development and manufacturing services including API development, oral solid dose, softgels, steriles manufacturing, biologics, viral vectors, and mRNA production for pharmaceutical and biotechnology sponsors
2. Clinical Trial Services: Services including clinical trial logistics, clinical packaging, clinical labeling, cold chain logistics, comparator sourcing, and clinical supply chain management
3. Regulatory Services: Regulatory support services for drug development and commercial manufacturing compliance

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Henogen is a biotechnology company addressing biomanufacturing issues under the general umbrella "from gene to the clinical product." The company provides outsourced biomanufacturing and development services to therapeutic developers requiring specialized capabilities to advance biologic and gene-based therapies from early-stage development through clinical production.

Product overview

Patheon pharma services is a Contract Development and Manufacturing Organization (CDMO) providing comprehensive pharmaceutical services under Thermo Fisher Scientific. The company offers an integrated platform of services across the drug development lifecycle, including Small Molecule Services (API development, oral solid dose, softgels, steriles), Large Molecule Services (biologics), Advanced Therapies (viral vectors, mRNA), Clinical Trial Services (manufacturing, packaging, labeling, logistics, cold chain management), Commercial Services, and Regulatory Services. The core offering is the Accelerator™ Drug Development platform, which provides 360° CDMO and CRO solutions combining scientific expertise, global site network (60+ locations), digital platforms, and flexible business models to accelerate treatments to patients faster.

Differentiator

Problem solved

Functional benefit

Brands

• Patheon: Global CDMO providing pharmaceutical contract development and manufacturing services including small molecule, large molecule, biologics, advanced therapies, viral vectors, mRNA, clinical trial services, and commercial manufacturing.

Products and services

• Biomanufacturing Services (Gene to Clinical Product)

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators2 records

Direct peers

• Vibalogics: Specialist CDMO focused on viral vectors for gene therapy and vaccine manufacturing, with operations in Europe and the US. Closely comparable to Henogen as a niche viral vector CDMO serving gene therapy developers.
• Catalent: Global CDMO with significant viral vector and gene therapy manufacturing capabilities serving biotech and pharma sponsors across the drug development lifecycle. Directly comparable to Henogen as a contract manufacturer of advanced therapies, with substantially larger scale.
• AGC Biologics: Global CDMO providing contract development and manufacturing services for biologics, cell and gene therapies, and viral vectors. Directly comparable to Henogen as a specialized viral vector and gene therapy CDMO serving biotech and pharma sponsors.
• WuXi Biologics: Global biologics CDMO providing end-to-end contract development and manufacturing services from cell line development to commercial manufacturing. Comparable to Henogen in offering integrated biologics and advanced therapy CDMO services to pharma and biotech sponsors worldwide.
• Samsung Biologics: Large-scale CDMO providing contract development and manufacturing services for biologics, with growing advanced therapy capabilities. Comparable to Henogen in serving biotech/pharma sponsors with contract manufacturing services, though at significantly larger scale.
• Lonza Group: One of the world's largest CDMOs with dedicated cell and gene therapy manufacturing capacity across multiple sites. Directly comparable to Henogen as a contract manufacturer of viral vectors and biologics, with broader modality coverage and larger scale.

Regional players

• Cell and Gene Therapy Catapult: UK-based cell and gene therapy manufacturing and innovation center providing process development and GMP manufacturing services to therapy developers. Comparable to Henogen as an advanced therapy CDMO serving European gene therapy sponsors, though operating as a non-profit Catapult rather than a private commercial entity.

Broad incumbents

• Charles River Laboratories: Large CRO/CDMO offering biologics and viral vector manufacturing services alongside a broader discovery and safety assessment portfolio. Comparable to Henogen in providing contract manufacturing services to biotech sponsors, though as part of a much broader scientific services portfolio.
• Boehringer Ingelheim BioXcellence: CDMO business of Boehringer Ingelheim offering contract development and manufacturing services for biologics, including cell and gene therapy capabilities. Comparable to Henogen as a pharma-affiliated CDMO serving biotech and pharma sponsors across biologics and advanced therapies.

Emerging players

• Brammer Bio: Viral vector and gene therapy CDMO acquired by Thermo Fisher Scientific in 2019 (now part of the same parent network as Henogen via Patheon). Closely comparable in modality and customer base; now effectively a sister operation within the same Thermo Fisher CDMO portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Henogen